ABOS — Acumen Pharmaceuticals Balance Sheet
0.000.00%
- $65.42m
- -$76.72m
- 17
- 51
- 20
- 19
Annual balance sheet for Acumen Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 43.8 | 194 | 178 | 244 | 172 |
Net Total Receivables | 0.109 | 0 | — | — | 0.398 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 44.4 | 199 | 180 | 247 | 178 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | 0.036 | 0.27 | 0.503 | 0.339 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 44.4 | 230 | 197 | 310 | 239 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.37 | 5.15 | 7.81 | 13 | 27.6 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.37 | 5.15 | 7.81 | 43.2 | 57.2 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 38.1 | 225 | 189 | 267 | 182 |
Total Liabilities & Shareholders' Equity | 44.4 | 230 | 197 | 310 | 239 |
Total Common Shares Outstanding |